Literature DB >> 26622435

Construction of orthotopic xenograft mouse models for human pancreatic cancer.

Lei Dai1, Caide Lu1, X I Yu2, Long-Jun Dai3, Jeff X Zhou4.   

Abstract

Animal models are indispensable for the study of tumorigenesis and the development of anti-cancer drugs for human pancreatic cancer. In the present study, two orthotopic xenograft mouse models were developed. AsPC-1 human pancreatic cancer cells were stably labeled with red fluorescent protein (RFP) and injected subcutaneously into nude mice. For the orthotopic tumor mass model, the formed subcutaneous tumors were cut into blocks and implanted into the pancreas of nude mice via laparotomy. For the Matrigel™ tumor block model, solidified Matrigel containing RFP-labeled AsPC-1 cells was cut into blocks and implanted into the pancreas of nude mice. A subcutaneous tumor xenograft model was used as a control. Tumor growth and metastasis were assessed using an in vivo fluorescence imaging system. Thirty-six days after implantation, all mice from the two orthotopic xenograft models (n=20 per group) and 55% of the subcutaneous xenograft mice (n=20) developed tumors. The tumor growth rate was significantly higher in the orthotopic models than that in the subcutaneous model (P<0.01). Metastasis to organs such as the liver was observed in the orthotopic tumor models. Histological examination showed that the tumors were poorly differentiated adenocarcinomas. In conclusion, two orthotopic xenograft mouse models of human pancreatic cancer were established; these exhibited greater tumor growth and metastasis than the subcutaneous xenograft mouse model.

Entities:  

Keywords:  orthotopic tumor model; pancreatic carcinoma; xenograft tumor model

Year:  2015        PMID: 26622435      PMCID: PMC4533213          DOI: 10.3892/etm.2015.2642

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  15 in total

Review 1.  Randomized clinical trials in pancreatic cancer.

Authors:  Alexander Stojadinovic; Axel Hoos; Murray F Brennan; Kevin C P Conlon
Journal:  Surg Oncol Clin N Am       Date:  2002-01       Impact factor: 3.495

Review 2.  Tumor-host interactions: a far-reaching relationship.

Authors:  Sandra S McAllister; Robert A Weinberg
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

3.  Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.

Authors:  Peter Büchler; Howard A Reber; Mendel M Roth; Mark Shiroishi; Helmut Friess; Oscar J Hines
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

4.  Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma.

Authors:  Mehrdad Nikfarjam; Dannel Yeo; Hong He; Graham Baldwin; Theodora Fifis; Patricia Costa; Bryan Tan; Eunice Yang; Shu wen Wen; Christopher Christophi
Journal:  J Invest Surg       Date:  2013-08-19       Impact factor: 2.533

Review 5.  Recent progress in pancreatic cancer.

Authors:  Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban
Journal:  CA Cancer J Clin       Date:  2013-07-15       Impact factor: 508.702

6.  Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

Authors:  Giuseppe Colucci; Roberto Labianca; Francesco Di Costanzo; Vittorio Gebbia; Giacomo Cartenì; Bruno Massidda; Elisa Dapretto; Luigi Manzione; Elena Piazza; Mirella Sannicolò; Marco Ciaparrone; Luigi Cavanna; Francesco Giuliani; Evaristo Maiello; Antonio Testa; Paolo Pederzoli; Massimo Falconi; Ciro Gallo; Massimo Di Maio; Francesco Perrone
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

Review 7.  Adjuvant therapy following resection for pancreatic adenocarcinoma.

Authors:  Murray F Brennan
Journal:  Surg Oncol Clin N Am       Date:  2004-10       Impact factor: 3.495

8.  Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

Authors:  Elizabeth Poplin; Yang Feng; Jordan Berlin; Mace L Rothenberg; Howard Hochster; Edith Mitchell; Steven Alberts; Peter O'Dwyer; Daniel Haller; Paul Catalano; David Cella; Al Bowen Benson
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

9.  Fetuin-A (α2HS-glycoprotein) is a serum chemo-attractant that also promotes invasion of tumor cells through Matrigel.

Authors:  Gladys N Nangami; Kurt Watson; Kitani Parker-Johnson; Kelechi O Okereke; Amos Sakwe; Pamela Thompson; Nanna Frimpong; Josiah Ochieng
Journal:  Biochem Biophys Res Commun       Date:  2013-08-07       Impact factor: 3.575

10.  Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.

Authors:  Tanja Hakkarainen; Merja Särkioja; Petri Lehenkari; Susanna Miettinen; Timo Ylikomi; Riitta Suuronen; Renee A Desmond; Anna Kanerva; Akseli Hemminki
Journal:  Hum Gene Ther       Date:  2007-07       Impact factor: 5.695

View more
  14 in total

Review 1.  Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Authors:  Annette T Byrne; Denis G Alférez; Frédéric Amant; Daniela Annibali; Joaquín Arribas; Andrew V Biankin; Alejandra Bruna; Eva Budinská; Carlos Caldas; David K Chang; Robert B Clarke; Hans Clevers; George Coukos; Virginie Dangles-Marie; S Gail Eckhardt; Eva Gonzalez-Suarez; Els Hermans; Manuel Hidalgo; Monika A Jarzabek; Steven de Jong; Jos Jonkers; Kristel Kemper; Luisa Lanfrancone; Gunhild Mari Mælandsmo; Elisabetta Marangoni; Jean-Christophe Marine; Enzo Medico; Jens Henrik Norum; Héctor G Palmer; Daniel S Peeper; Pier Giuseppe Pelicci; Alejandro Piris-Gimenez; Sergio Roman-Roman; Oscar M Rueda; Joan Seoane; Violeta Serra; Laura Soucek; Dominique Vanhecke; Alberto Villanueva; Emilie Vinolo; Andrea Bertotti; Livio Trusolino
Journal:  Nat Rev Cancer       Date:  2017-01-20       Impact factor: 60.716

2.  Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.

Authors:  Amira Elgogary; Qingguo Xu; Brad Poore; Jesse Alt; Sarah C Zimmermann; Liang Zhao; Jie Fu; Baiwei Chen; Shiyu Xia; Yanfei Liu; Marc Neisser; Christopher Nguyen; Ramon Lee; Joshua K Park; Juvenal Reyes; Thomas Hartung; Camilo Rojas; Rana Rais; Takashi Tsukamoto; Gregg L Semenza; Justin Hanes; Barbara S Slusher; Anne Le
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-24       Impact factor: 11.205

3.  In Vivo Bioluminescence Tomography Center of Mass-Guided Conformal Irradiation.

Authors:  Zijian Deng; Xiangkun Xu; Tomas Garzon-Muvdi; Yuanxuan Xia; Eileen Kim; Zineb Belcaid; Andrew Luksik; Russell Maxwell; John Choi; Hailun Wang; Jingjing Yu; Iulian Iordachita; Michael Lim; John W Wong; Ken Kang-Hsin Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-11-15       Impact factor: 7.038

4.  iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.

Authors:  Lijun Ma; Qiubing Chen; Panpan Ma; Moon Kwon Han; Zhigang Xu; Yuejun Kang; Bo Xiao; Didier Merlin
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

5.  Orthotopic Models of Pancreatic Cancer to Study PDT.

Authors:  Girgis Obaid; Zhiming Mai; Tayyaba Hasan
Journal:  Methods Mol Biol       Date:  2022

6.  ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma.

Authors:  Miao Li; Weijun Wei; Todd E Barnhart; Dawei Jiang; Tianye Cao; Kevin Fan; Jonathan W Engle; Jianjun Liu; Weiyu Chen; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-03       Impact factor: 10.057

7.  Difference in morphology and interactome profiles between orthotopic and subcutaneous gastric cancer xenograft models.

Authors:  Kiyotaka Nakano; Takashi Nishizawa; Daisuke Komura; Etsuko Fujii; Makoto Monnai; Atsuhiko Kato; Shin-Ichi Funahashi; Shumpei Ishikawa; Masami Suzuki
Journal:  J Toxicol Pathol       Date:  2018-08-13       Impact factor: 1.628

8.  Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer.

Authors:  Karl Roland Ehrenberg; Jianpeng Gao; Felix Oppel; Stephanie Frank; Na Kang; Sebastian M Dieter; Friederike Herbst; Lino Möhrmann; Taronish D Dubash; Erik R Schulz; Hendrik Strakerjahn; Klara M Giessler; Sarah Weber; Ava Oberlack; Eva-Maria Rief; Oliver Strobel; Frank Bergmann; Felix Lasitschka; Jürgen Weitz; Hanno Glimm; Claudia R Ball
Journal:  Cells       Date:  2019-02-10       Impact factor: 6.600

9.  Development of orthotopic tumour models using ultrasound-guided intrahepatic injection.

Authors:  L E McVeigh; I Wijetunga; N Ingram; G Marston; R Prasad; A F Markham; P L Coletta
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

Review 10.  Modeling neoplastic disease with spheroids and organoids.

Authors:  Michele Zanoni; Michela Cortesi; Alice Zamagni; Chiara Arienti; Sara Pignatta; Anna Tesei
Journal:  J Hematol Oncol       Date:  2020-07-16       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.